Clearing
the way
Clearing the way
Clinical-grade psychedelics that combine lab rigor with sustainability, enabling reproducible research and responsible access for next-generation mental health treatments.
Our Compounds
Psilocybin
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
Psilocybin
+
Applications
Depression
Anxiety
PTSD
Addiction
About
Psilocybin primarily acts by interacting with serotonin receptors in the brain, particularly the 5-HT2A receptor.. When psilocybin is ingested, it is converted into psilocin, which binds to these receptors, altering neural activity and leading to changes in perception, mood, and cognition.
DMT
+
Applications
Depression
Anxiety
About
DMT acts by binding to serotonin receptors, particularly the 5-HT2A receptor, similar to other psychedelics like psilocybin. This interaction disrupts normal neural signaling, leading to intense visual and emotional experiences that are often short-lived but profound.
5-MeO-DMT
+
Applications
Depression
Anxiety
Trauma
About
Recent Phase 2b trials of intranasal 5-MeO-DMT (BPL-003) revealed rapid and sustained antidepressant effects, with nearly half of participants achieving remission after two doses. These findings highlight its potential as a fast-acting alternative to traditional antidepressants.
Bufotenine
+
Applications
Mood disorders
Substance addiction
About
Bufotenine is a naturally occurring tryptamine compound structurally similar to serotonin, found in certain toads, plants, and fungi. It interacts with serotonin receptors, particularly 5-HT2A, 5-HT2B, and 5-HT2C, potentially producing psychoactive effects.
We are pioneering
clinical-grade APIs
clinical-grade APIs and
and finished drug products
through biosynthesis,
and finished drug products
measurable, consistent, and sustainable compounds
through biosynthesis, measurable, consistent, and sustainable compounds
redefining how we approach mental health.
We are pioneering
clinical-grade APIs
clinical-grade APIs
and finished drug products
through biosynthesis,
through
measurable, consistent, and sustainable compounds
biosynthesis, measurable, consistent, and sustainable compounds
redefining how we approach mental health.
Tailored for
Scientific research
Scientific research
Scientific research
Clinical trials
Clinical trials
Clinical trials
Commercial applications
Commercial applications
Commercial applications
Today’s treatments are not enough.
The growing gap
Mental health disorders affect more people than ever — yet innovation in treatment has fallen behind.
The growing gap
Mental health disorders affect more people than ever — yet innovation in treatment has fallen behind.
The growing gap
Mental health disorders affect more people than ever — yet innovation in treatment has fallen behind.
The limits of traditional care
Existing solutions often fail to provide lasting relief. High costs, side effects, and accessibility barriers leave millions without effective options.
The limits of traditional care
Existing solutions often fail to provide lasting relief. High costs, side effects, and accessibility barriers leave millions without effective options.
The limits of traditional care
Existing solutions often fail to provide lasting relief. High costs, side effects, and accessibility barriers leave millions without effective options.
The research bottleneck
Scientists and clinicians working with psychedelics face a major constraint: the lack of consistent, scalable, clinical-grade compounds to advance studies.
The research bottleneck
Scientists and clinicians working with psychedelics face a major constraint: the lack of consistent, scalable, clinical-grade compounds to advance studies.
The research bottleneck
Scientists and clinicians working with psychedelics face a major constraint: the lack of consistent, scalable, clinical-grade compounds to advance studies.
Our Solution
Our Solution
Our Solution
Psychedelic compounds awaken the
brain’s ability to rebuild and rewire
Promote Neuroplasticity
Psychedelic compounds promote new neural connections, supporting adaptive thinking.
From daily pills to annual dosing
2 sessions
2 per year are enough to maintain long-term benefits.
Root-Cause Focus
Patients show sustained improvement after a single guided session.
A more open, interconnected
brain under psilocybin
A more open, interconnected
brain under psilocybin
Before
After
Before
After
Placebo
Placebo
Placebo
Psilocybin
Psilocybin
Psilocybin
Our mission is to make next-generation therapies accessible to researchers, clinicians, and patients worldwide, to clear the way toward a healthier mind for all.
Our mission is to make next-generation therapies accessible to researchers, clinicians, and patients worldwide, to clear the way toward a healthier mind for all.
The ones who trust us
View our Pitch Deck
Discover Eywa in Depth to learn more about our science and our mission
Download Deck
Download Deck
Download Deck
Eywa Academy
Our educational hub, a space to learn, connect, and lead the conversation on psychedelics and mental health innovation. Discover conversations and discoveries redefining how we understand the mind.
Let’s clear the way
for what’s next.
Whether you’re a researcher, a practitioner, or simply curious about the future of mental health, we’d love to hear from you.
Let’s clear the way
for what’s next.
Whether you’re a researcher, a practitioner, or simply curious about the future of mental health, we’d love to hear from you.
Let’s clear the way
for what’s next.
Whether you’re a researcher, a practitioner, or simply curious about the future of mental health, we’d love to hear from you.